Oncoinvent Asa · OSL:ONCIN
Oncoinvent Asa — DNB Carnegie Nordic Healthcare Conference 2026
16 slides from Oncoinvent Asa's conference presentation, Mar 10, 2026
Slide 1: Transforming cancer care through direct alpha therapy
Oncoinvent Transforming cancer care through direct alpha therapy DNB Carnegie Nordic Healthcare Conference March 10, 2026
Slide 2: Peritoneal carcinomatosis is the spread of cancer to the abdominal cavity
Peritoneal carcinomatosis is the spread of cancer to the abdominal cavity: a lethal stage of disease with very high unmet need • Cancer in the peritoneum is an advanced stage of disease, Secondary extraperitoneal origin Secondary intraperitoneal origin originating from locoregional spread from vario
Slide 3: Radspherin kills residual microscopic cancer cells after surgical resection
INVESTMENT THESIS Radspherin® kills residual microscopic cancer cells after surgical resection, which drive the high recurrence rate in peritoneal metastasis, a key cause of mortality • Radspherin® is an intraperitoneal alpha therapy carried by radium-224-laden microparticles • A single dose is admi
Slide 4: Radspherin's mechanism of action, direct alpha therapy, offers potent local control
Radspherin’s mechanism of action, direct alpha therapy, offers potent local control for peritoneal disease while allowing healthy tissue to recover • Alpha radiation is highly effective at close Alpha particles are high energy but only reach about 0.1 mm, or ~10 cells deep in tissue range; micropart
Slide 5: Our first disease focus is Ovarian Cancer
Our first disease focus is Ovarian Cancer, where most patients present with peritoneal disease at diagnosis, the majority of whom relapse after surgery 70% of all ovarian cancer patients have Up to 85% relapse after surgical Past this stage, disease is largely incurable peritoneal metastasis at diag
Slide 6: Radspherin is a much-needed addition to prevent recurrence of peritoneal metastasis
Radspherin is a much-needed addition prevent recurrence of peritoneal metastasis, and therefore (progression-free) survival Systemic therapy has …local control is crucial, but options …Radspherin complements these limited effect… are limited… options Systemic chemotherapy > Debulking surgery > • Add
Slide 7: Radspherin has an inherent edge in its safety profile
Through its design, Radspherin® has an inherent edge in its safety profile through its self-contained nature within the peritoneal cavity High activity dose delivered Ovarian cancer Phase 1 safety summary (n=21) directly to the • No increase of rates of events with increasing dose peritoneum/periton
Slide 8: Our current focus is on Ovarian Cancer, with pipeline opportunities
Our current focus is on Ovarian Cancer, with pipeline opportunities leveraging the same drug in CRC and several other malignancies 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 RAD-18-001 Ovarian, recurrent phase 1 Platinum-sensitive recurrent patients after secondary debulking RAD-18-002 Colorectal phase
Slide 9: Final readouts so far show strong signals of peritoneal control
Final readouts so far show strong signals of peritoneal control Historical controls Radspherin® “These final results are truly encouraging, suggesting that Ovarian Radspherin® could help delay disease progression and offer Ph1 Data patients hope for longer, healthier lives.” n=10 in highest dose 24
Slide 10: We have been operating our own GMP facility since 2018
We have been operating our own GMP facility since 2018, through experience and sustained development, we scaled capacity significantly Oncoinvent has in-house GMP 224Ra produced from 228Th, which Microparticles and finished goods production capability has multiple sources produced in-house • Unique
Slide 11: The full Radspherin process is done in-house
The full Radspherin® process, including the manufacture of its raw materials is done in-house, improving reliability, quality and cost Overview of the Radspherin® production process Raw material input Combination Final product Elution of the alpha- emitter radium-224 Thorium-228 generator column Rad
Slide 12: Radspherin fills a unique pocket of value in a high-demand area
Radspherin® fills a unique pocket of value in a high-demand area with equally high barriers to entry Procedure-based Biologics / SoC Device Radiopharmaceuticals locoregional chemo immunotherapies Radspherin® Farletuzumab KORJUNY® IMNN-001 Systemic TTFields chemo XLNT-1 HIPEC PIPAC ²¹¹At- Development
Slide 13: Radspherin in ovarian cancer alone has blockbuster potential in US+EU5
Radspherin® in ovarian cancer alone has blockbuster potential in US+EU5, Ovarian cancer US EU 5 Total Colorectal cancer US EU 5 Total Example for follow-up Incidence OC1 25 000 32 000 195 indications: Incidence CRC1 310 000 000 Annual number of peritoneal Proportion with Proportion of patients metas
Slide 14: Radspherin has solid multilayer intellectual property protection
Radspherin® has solid multilayer intellectual property protection Radspherin® composition of matter & use • Granted in US, EU, China, Japan and additional countries • Patent expiry 2035 (2036 in some countries) with an option for 5 years extension Radspherin® formulation • Filed in 2021 in: USA, Eur
Slide 15: Early signals of efficacy and safety, platform potential, experienced team
Early signals of efficacy and safety, platform potential across many high-unmet need indications, and an experienced team with a proven track record Optimized use of a proven mode of action with clear efficacy signals 1 • In Ovarian Cancer (Ph1) 90% remain without peritoneal recurrence 24 months in
Slide 16: invent
invent
Oncoinvent — DNB Carnegie Nordic Healthcare Conference 2026 on 6ix